Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ivermectin: a long-acting microfilaricidal agent.

E I Ette1, W O Thomas, J I Achumba

  • 1University of Lagos, Nigeria.

DICP : the Annals of Pharmacotherapy
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designing population pharmacokinetic studies: performance of mixed designs.

European journal of drug metabolism and pharmacokinetics·2001
Same author

Artificial skin in the treatment of a large congenital nevus.

Southern medical journal·2001
Same author

The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.

Clinical pharmacokinetics·2001
Same author

The process of knowledge discovery from large pharmacokinetic data sets.

Journal of clinical pharmacology·2001
Same author

Laser resurfacing complication.

Southern medical journal·1999
Same author

Population pharmacokinetics. A regulatory perspective.

Clinical pharmacokinetics·1999
Same journal

Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin.

DICP : the annals of pharmacotherapy·1991
Same journal

Ketorolac formulary restriction and usage evaluation.

DICP : the annals of pharmacotherapy·1991
Same journal

Oral vancomycin-induced rash: case report and review of the literature.

DICP : the annals of pharmacotherapy·1991
Same journal

Imipenem/cilastatin drug utilization evaluation in a large community hospital.

DICP : the annals of pharmacotherapy·1991
Same journal

Pharmacist involvement in Society of Critical Care Medicine.

DICP : the annals of pharmacotherapy·1991
Same journal

Early anticoagulation therapy in deep vein thrombosis.

DICP : the annals of pharmacotherapy·1991
See all related articles

Ivermectin effectively kills Onchocerca volvulus microfilariae, reducing transmission and offering a safer alternative to diethylcarbamazine for onchocerciasis treatment.

Area of Science:

  • Pharmacology
  • Parasitology
  • Tropical Medicine

Background:

  • Ivermectin is a potent macrocyclic lactone with broad-spectrum activity against parasites.
  • Onchocerciasis, caused by Onchocerca volvulus, is a significant public health concern transmitted by black flies.
  • Diethylcarbamazine is the current standard treatment but is associated with severe Mazzoti-type reactions.

Purpose of the Study:

  • To evaluate the efficacy and safety of ivermectin in treating onchocerciasis.
  • To compare ivermectin's side effect profile with diethylcarbamazine.

Main Methods:

  • Clinical trials involving oral administration of ivermectin (0.15-0.2 mg/kg).
  • Assessment of microfilaricidal activity and reduction in dermal microfilariae density.

Related Experiment Videos

  • Comparison of adverse event profiles between ivermectin and diethylcarbamazine.

    • Main Results:

    • Ivermectin demonstrated significant microfilaricidal activity, reducing dermal microfilariae density to near zero for 6-12 months post-dose.
    • The drug exhibited a favorable pharmacokinetic profile with a rapid time to maximum concentration and a defined elimination half-life.
    • Controlled trials indicated ivermectin is associated with milder side effects compared to diethylcarbamazine, notably lacking severe Mazzoti-type reactions.

    Conclusions:

    • Ivermectin is an effective and safer alternative for onchocerciasis therapy.
    • The drug's superior tolerability profile warrants its adoption as the preferred treatment over diethylcarbamazine.